Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Herbst on the Evolution of Targeted Therapies for EGFR+ NSCLC

August 2nd 2024

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Dr Rotow on Challenges With Targeting CNS Metastases in Lung Cancer

August 1st 2024

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Dr Backhus on Defining Borderline-Resectable Lung Cancer

August 1st 2024

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Dr Shields on Incorporating Tarlatamab into Clinical Practice for ES-SCLC

July 30th 2024

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Dr Riess on Advancements in Thymic Epithelial Malignancy Management

July 30th 2024

Jonathan W. Riess, MD, MS, discusses advancements, as well as unmet needs in the management of thymic malignancies.

Examining Key Data from DAREON-8

July 30th 2024

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

July 30th 2024

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

Liquid Biopsy in Oncology: Have We Just Scratched the Surface?

July 30th 2024

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

Dr Patel on Areas of Advancement in the NSCLC Treatment Landscape

July 30th 2024

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

Dr Desai on Unmet Needs With Chemoimmunotherapy in NSCLC

July 30th 2024

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Dr Sen on the Goal to Identify Actionable Biomarkers of Interest in SCLC

July 30th 2024

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.

Dr Peters on the Use of Biomarkers to Inform Treatment Decision-Making in NSCLC

July 30th 2024

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer

July 30th 2024

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial

July 30th 2024

Misako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.

Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

July 29th 2024

Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

July 29th 2024

China’s NMPA Accepts sBLA for Ivonescimab in First-Line PD-L1+ NSCLC

July 29th 2024

China’s NMPA has accepted an sBLA for ivonescimab in first-line, PD-L1–positive non–small cell lung cancer.

Experts Delve into Case-Based Discussions of Locally Advanced Lung Cancer Management

July 29th 2024

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.